KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Acquisitions (2020 - 2025)

Gilead Sciences (GILD) has disclosed Acquisitions for 9 consecutive years, with $609.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Acquisitions rose 712.0% year-over-year to $609.0 million, compared with a TTM value of $1.1 billion through Dec 2025, down 77.89%, and an annual FY2025 reading of $1.1 billion, down 77.89% over the prior year.
  • Acquisitions was $609.0 million for Q4 2025 at Gilead Sciences, up from $167.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $4.0 billion in Q1 2024 and bottomed at $21.0 million in Q2 2025.
  • Average Acquisitions over 5 years is $522.2 million, with a median of $258.0 million recorded in 2023.
  • Peak annual rise in Acquisitions hit 1892.06% in 2021, while the deepest fall reached 99.78% in 2021.
  • Year by year, Acquisitions stood at $44.0 million in 2021, then skyrocketed by 395.45% to $218.0 million in 2022, then rose by 27.98% to $279.0 million in 2023, then plummeted by 73.12% to $75.0 million in 2024, then skyrocketed by 712.0% to $609.0 million in 2025.
  • Business Quant data shows Acquisitions for GILD at $609.0 million in Q4 2025, $167.0 million in Q3 2025, and $21.0 million in Q2 2025.